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Association between MRD dynamics 
and outcomes for AML patients 
following myeloablative HCT, stratified 
by positive/negative MRD status. 
Kaplan-Meier estimate of relapse free 
survival following myeloablative 
allogeneic HCT for adults with AML. 
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Since the inception of hematopoietic cell transplantation (HCT) many studies have found this therapy 
to significantly improve patient outcomes and survival. However, as with all clinical studies, success 
is determined for a population of patients, and individual responses can range widely. In acute 
myeloid leukemia (AML), patient relapse after HCT has been correlated with 'depth of remission'. 
The unique nature of AML as a hematopoietic cancer makes assessing remission very difficult. 
Morphological remission is determined by microscopic review of marrow and peripheral blood cell 
smears. However, advances in diagnostic tools have revealed that some patients in morphological 
remission still harbor cancer cells in their body. This sub-microscopic cancer cell population is 
termed MRD and its presence correlates with high relapse rates and worse outcomes for patients. 
MRD is thought to result from rare leukemia cells that were resistant to the therapy that led to 
morphological remission, and is prognostic for high risk of relapse. In transplant patients MRD has 
largely been evaluated using highly sensitive methods like flow cytometry at a single point, either 
before or after HCT. In a recent study published in Leukemia, Dr. Roland Walter and colleagues in 
the Clinical Research Division instead evaluated MRD both prior to and after HCT in order to 
understand how disease burden dynamics correlate with patient outcomes.  
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One of the main challenges to understanding MRD is reliably detecting it. In this study MRD was 
detected with multi-parameter flow cytometry. This technique uses three antibody combinations to 
detect 17 unique cellular markers and the presence of residual leukemia cells is determined by 
visual inspection for variation among these markers. The present study consisted of 311 AML 
patients who were in either first or second morphological remission prior to HCT. Patients' MRD 
status before HCT was routinely determined as standard care leading up to transplant, while post 
transplant MRD status was determined 21 to 35 days after the procedure. To understand how MRD 
affected patient outcomes (survival, relapse, and non-relapse mortality) patient follow up continued 
up to 8 years after transplant. 
MRD likely consists of therapy resistant leukemia cells and thus may correlate to patient outcomes 
differently if a patient has experienced relapse. Patients were grouped by first or second 
morphological remission and these two groups were further sub-divided by MRD status prior to HCT 
(positive or negative). As the authors have shown in a previous publication, relapse-free survival 
correlated with negative MRD status, independent of remission number. This suggests a key to 
patient survival is achieving MRD negative status regardless of a patient’s therapeutic history. Next, 
researchers compared the prognostic value of MRD status before and after HCT. The most common 
patient group was pre-HCT MRD negative patients that remained MRD negative. Conversion to 
MRD positive status after HCT was rarely observed. Oppositely, pre-HCT MRD positive patients 
most commonly were MRD negative post-HCT, though some were unchanged. When patients were 
grouped by both their pre- and post-HCT MRD status it became strikingly clear that pre-HCT MRD 
negative patients who remained MRD negative had the highest survival outcomes, while patients 
that were MRD positive either pre or post-HCT were at increased risk for relapse. 
In general, AML patients undergoing HCT are not only at risk of relapse, but also graft versus host 
disease (GVHD) where donor immune cells elicit a response against host tissue. Possible GVHD 
necessitates immunosuppression in transplant patients, which also carries health risks due to 
infection. When patient groups were analyzed for these non-relapse mortalities the risk did not seem 
to correlate with MRD status. Said Dr. Walter, "I think the fact that the outcome difference between 
MRDpos and MRDneg patients is primarily due to differences in relapse risk just speaks for the fact 
that MRD is a marker of inherent insensitivity of the leukemia to (prior) therapy and, thus, a marker 
for disease recurrence, rather than a marker to tolerability of transplant. This association makes the 
case that a major focus should be in finding treatment strategies that reduce relapse risk in MRDpos 
patients." 
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While pre-HCT and post-HCT MRD status were quite predictive of patient survival, it is still unclear if 
the presence of MRD actually drives relapse, or is merely a predictor. Dr. Walter explained the next 
step for these studies, "I think the fundamental study that needs to be done is a study that 
documents the value of MRD directed therapy. That is, there is no doubt that MRD identifies patients 
at high risk of relapse and short survival. What is not established with solid data is the idea that 
treating MRD will improve outcomes." This work begs for follow up studies that may dramatically 
change the approach to patient care for AML. 
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